Stock Scorecard



Stock Summary for Verona Pharma Plc (VRNA) - $67.57 as of 5/13/2025 9:15:30 PM EST

Total Score

7 out of 30

Safety Score

43 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for VRNA

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for VRNA

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for VRNA

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for VRNA

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for VRNA (43 out of 100)

Stock Price Rating (Max of 10) 9
Historical Stock Price Rating (Max of 10) 4
Stock Price Trend (Max of 10) 10
Book Value (Max of 10) 3
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 8
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for VRNA

Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025 - Verona Pharma ( NASDAQ:VRNA ) 5/6/2025 10:00:00 AM
Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025 5/6/2025 10:00:00 AM
Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update 4/29/2025 10:00:00 AM
Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update 4/15/2025 10:00:00 AM
Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update - Verona Pharma ( NASDAQ:VRNA ) 4/15/2025 10:00:00 AM
Verona Pharma Options Trading: A Deep Dive into Market Sentiment - Verona Pharma ( NASDAQ:VRNA ) 3/28/2025 7:45:00 PM
Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS 3/28/2025 11:00:00 AM
Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS - Verona Pharma ( NASDAQ:VRNA ) 3/28/2025 11:00:00 AM
Beat the Market the Zacks Way: Verona, Visa, Starbucks in Focus 3/3/2025 1:08:00 PM
Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update 2/27/2025 11:00:00 AM

Financial Details for VRNA

Company Overview

Ticker VRNA
Company Name Verona Pharma Plc
Country USA
Description Verona Pharma plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company is headquartered in London, the United Kingdom.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 3/31/2025
Next Earnings Date N/A

Stock Price History

Last Day Price 67.57
Price 4 Years Ago 6.72
Last Day Price Updated 5/13/2025 9:15:30 PM EST
Last Day Volume 751,081
Average Daily Volume 1,596,833
52-Week High 74.18
52-Week Low 11.39
Last Price to 52 Week Low 493.24%

Valuation Measures

Trailing PE N/A
Industry PE 29.04
Sector PE 49.22
5-Year Average PE -653.75
Free Cash Flow Ratio 14.32
Industry Free Cash Flow Ratio 19.04
Sector Free Cash Flow Ratio 31.82
Current Ratio Most Recent Quarter 8.86
Total Cash Per Share 4.72
Book Value Per Share Most Recent Quarter 2.49
Price to Book Ratio 25.37
Industry Price to Book Ratio 38.21
Sector Price to Book Ratio 30.58
Price to Sales Ratio Twelve Trailing Months 75.90
Industry Price to Sales Ratio Twelve Trailing Months 93.50
Sector Price to Sales Ratio Twelve Trailing Months 25.54
Analyst Buy Ratings 7
Analyst Strong Buy Ratings 3

Share Statistics

Total Shares Outstanding 85,132,000
Market Capitalization 5,752,369,240
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -218.96%
Reported EPS 12 Trailing Months -2.00
Reported EPS Past Year -0.02
Reported EPS Prior Year -2.16
Net Income Twelve Trailing Months -164,022,409
Net Income Past Year -173,418,000
Net Income Prior Year -54,369,000
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 609.54%
Operating Margin Twelve Trailing Months -13.50%

Balance Sheet

Total Cash Most Recent Quarter 401,415,000
Total Cash Past Year 399,757,000
Total Cash Prior Year 271,772,000
Net Cash Position Most Recent Quarter 159,673,000
Net Cash Position Past Year 279,416,000
Long Term Debt Past Year 120,341,000
Long Term Debt Prior Year 48,374,000
Total Debt Most Recent Quarter 241,742,000
Equity to Debt Ratio Past Year 0.63
Equity to Debt Ratio Most Recent Quarter 0.48
Total Stockholder Equity Past Year 204,559,000
Total Stockholder Equity Prior Year 249,283,000
Total Stockholder Equity Most Recent Quarter 226,595,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -120,951,639
Free Cash Flow Per Share Twelve Trailing Months -1.42
Free Cash Flow Past Year -122,783,000
Free Cash Flow Prior Year -50,222,004

Options

Put/Call Ratio 1.44
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 3.03
MACD Signal 2.42
20-Day Bollinger Lower Band 44.17
20-Day Bollinger Middle Band 59.74
20-Day Bollinger Upper Band 75.31
Beta 0.20
RSI 58.12
50-Day SMA 39.39
150-Day SMA 24.07
200-Day SMA 19.38

System

Modified 5/13/2025 1:40:19 PM EST